Wenzhou Medical University

FDA Grants Orphan Drug Designation to China-Developed ApDC for Uveal Melanoma

- An Aptamer Drug Conjugate (ApDC) developed by Chinese researchers has received orphan drug designation from the FDA for uveal melanoma treatment. - The ApDC, developed by Hangzhou Institute of Medicine and Wenzhou Medical University, targets malignant uveal melanoma and liver metastatic tumors with improved safety. - Preclinical studies demonstrate the ApDC's efficacy in inhibiting ocular tumor growth and reducing metastasis to vital organs like the liver and lungs. - Clinical trials are planned to expedite the drug's application, offering new hope for uveal melanoma patients with limited treatment options.